cardiovascular-agents and Myasthenia-Gravis

Topics: Aged; Animals; Anti-Bacterial Agents; Anticonvulsants; Cardiovascular Agents; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Hormones; Humans; Motor Endplate; Myasthenia Gravis; Neuromuscular Junction; Penicillamine; Postoperative Complications; Psychotropic Drugs; Respiratory Insufficiency; Synaptic Transmission; Syndrome

Myasthenia gravis is an uncommon disease. The emergency physician should be cautious when prescribing medications to myasthenics for problems not related to myasthenia gravis. We have discussed some of those agents (Figure 3) that are recognized to cause exacerbation of MG or that may have the potential to exacerbate MG. We recommend that management of any medical or surgical problem of the myasthenic be done in consultation with a managing neurologist, and that either early follow-up or admission is necessary when these agents are used in the patient with myasthenia gravis.

Topics: Anti-Bacterial Agents; Anticonvulsants; Cardiovascular Agents; Drug-Related Side Effects and Adverse Reactions; Glucocorticoids; Humans; Myasthenia Gravis; Neuromuscular Blocking Agents; Psychotropic Drugs

Topics: Ammonium Compounds; Blood; Cardiovascular Agents; Child; Diagnosis; Endocrinology; Ephedrine; Guanidines; Humans; Muscle Relaxants, Central; Myasthenia Gravis; Neostigmine; Pathology; Physostigmine; Quaternary Ammonium Compounds; Respiratory Insufficiency; Spironolactone; Thymus Gland

Topics: Cardiovascular Agents; Electromyography; Humans; Liver Diseases; Muscle Relaxants, Central; Myasthenia Gravis; Neurology; Water-Electrolyte Balance

Topics: Cardiovascular Agents; Edrophonium; Humans; Muscle Relaxants, Central; Musculoskeletal System; Myasthenia Gravis

Topics: Cardiovascular Agents; Humans; Muscle Relaxants, Central; Myasthenia Gravis; Neuromuscular Junction; Synaptic Transmission

Topics: Cardiovascular Agents; Humans; Muscle Relaxants, Central; Myasthenia Gravis